Install
Ajanta Pharma to hold 47th annual general meeting on July 16 Indian Pharma Post Get the latest News & Research on Pharma industry, Viewpoints, Events, Videos, statistics, indianpharmapost.com
- 177articles · 30d
- 11+ hour agolatest article
- Aug 17, 2026earliest in window
- 89%with images
- 241avg words
- Medical 126
- Health & Wellness 92
- Economy, Business & Finance 79
- Health 66
- Business & Industrial 65
- Finance & Business 34
- Science & Technology 21
- News 14
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Osivax and GC Biopharma partner on next-generation flu vaccine
1+ week, 6+ day ago (55+ words) Dr. Rajesh Nair appointed CEO of Park Group of Hospitals India cuts malaria cases and deaths by nearly 80% over a decade IPC launches 12 reference standards to strengthen quality of phytopharma Cipla’s InvaGen plant in New York gets VAI status from…...
Pfizer and BioNTech bag FDA nod for XFG-targeted COVID-19 vaccine
2+ week, 4+ hour ago (75+ words) The vaccine is not appropriate for people who have experienced a severe allergic reaction after a previous dose of COMIRNATY Dr. Rajesh Nair appointed CEO of Park Group of Hospitals India cuts malaria cases and deaths by nearly 80% over a…...
Merck and Moderna report landmark Phase 3 success for personalized mRNA melanoma therapy
3+ week, 1+ day ago (70+ words) The trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, marking what the companies describe as the first positive Phase 3 readout Merck Moderna vaccine clinical NATCO Pharma’s Visakhapatnam facility receives 4 observations in…...
Merck and Moderna's mRNA cancer vaccine combo hits primary endpoint in landmark Phase 3 trial
3+ week, 3+ day ago (457+ words) Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (also known as V940 or mRNA-4157), an individualized mRNA-based neoantigen therapy, in combination with Merck's KEYTRUDA (pembrolizumab) as adjuvant treatment for patients with completely resected stage…...